1 June 2026 in Hepatology and Gastroenterology
Background. Identifying NS5A gene resistance mutations in patients with treatment failure is crucial for personalized therapy indication, making it possible to prevent repeated failures and achieve complete viral eradication. Objective. To assess the spectrum and prevalence of HCV NS5A gene drug resistance mutations in patients with virological failure of direct-acting antiviral (DAA) therapy based on the results of the 2018–2024 study. Material and methods. The study included 675 patients with virological failure after the treatment with NS5A inhibitors. HCV genotyping and resistance mutation detection were performed using Sanger sequencing of Core/E1 and NS5A genome fragments. Statistical data processing was performed using Statistica v.10. Results. HCV subtypes 3a, 1b, and 1a are predominant among patients with DAA therapy failure. Resistanceassociated mutations (RASs) were detected in 64,0% of cases. RASs were identified in 23,6% of cases for the subtype 1a, in 67,3% for the subtype 1b and in 75,9% for the subtype 3a. Overall, the RAS spectrum for the subtype 1b was broader than for the subtypes 1a and 3a. Conclusion. For the first time in the Republic of Belarus, the prevalence and profile of RAS in HCV-infected patients with DAA therapy failure were determined. HCV-3a exhibits the highest RAS prevalence compared to HCV-1a and HCV-1b. The predominance of multiple mutations requires a personalized approach to the therapy to achieve HCV elimination.
4 June 2026 in Medical and Biological Problems of Life Activity
Based on partial sequencing data of the S gene from 2 066 clinical samples, the spectrum of SARS-CoV-2 variants was determined and the characteristics of their spread in the Republic of Belarus in 2020–2021 were established. At the beginning of 2020, predominantly early «Wuhan» variants were identified: A.1 in Minsk and B.1 in the Vitebsk Region. In the 2nd–3rd quarters, all analyzed sequences belonged to variant B.1, which remained the leader in the 4th quarter (90,6%). Rare B.1 sublineages collectively accounted for 9,4%, among which variant B.1.1.374 predominated. Regional differences during this period were not significant (p>0,05). The Alpha variant displaced the early variants (including B.1.1.374) in the first quarter of 2021, becoming dominant. The Delta variant, represented predominantly by AY.4, began to active spread from May 2021 and by summer completely replaced Alpha. Regional differences in 2020–2021 were not significant (p>0,05).
15 October 2026 in Health and Ecology Issues
Objective
. To conduct a comparative analysis of the frequency and spectrum of resistance mutations to NS5A inhibitors in patients with hepatitis C virus (HCV) monoinfection and HCV/HIV coinfection after failed treatment with direct-acting antiviral drugs.
Materials and methods
. The study included 180 patients with HCV/HIV coinfection and 180 patients with HCV monoinfection who relapsed or reinfected after therapy containing NS5A inhibitors. Frequency matching was performed across groups by gender, age, and HCV subtype. HCV genotyping and resistance mutation detection were performed using Sanger sequencing of Core/E1 and NS5A genome fragments.
Results
. HCV subtype 3a was found to be dominant (53.9%) among the etiologic factors of virological failure in patients with HIV coinfection. The overall frequency of Resistance-Associated Substitutions (RAS) detection in the NS5A region was 60.6% in HIV coinfection and 66.1% in HCV monoinfection (p=0.283). Significant subtype-specific intergroup differences in the mutation spectrum were revealed for subtypes 1a, 1b, and 3a. In the case of subtype 3a, clinically significant highly resistant strains (A30K/S, Y93H, and their combinations with A62) prevailed in monoinfected patients, while polymorphisms associated with decreased sensitivity (mainly A62) prevailed in HIV coinfection. For subtype 1b, high-significance RAS with a leading role played by Y93H were more common in monoinfection, while complex profiles (A30Q+L31M±Y93H) were found in coinfection. For subtype 1a, highly resistant variants (Q30R, Y93C) predominated in coinfection, while mutations of moderate significance (M28T, L31V) predominated in monoinfection.
Conclusion
. The overall frequency of detection of resistance mutations in the NS5A gene did not differ significantly between the HIV coinfection and HCV monoinfection groups. However, the patterns of these mutations significantly depended on both the viral subtype and the presence of HIV coinfection. These data indicate the need to identify resistance mutations before repeat courses of therapy in patients with prior virological failure.
22 December 2024 in Biological Products. Prevention, Diagnosis, Treatment
INTRODUCTION. The high prevalence of mutations in the SARS-CoV-2 genome raises particular concerns about the resistance of the virus to current antiviral therapy, including inhibitors of the main protease, or 3C-like protease (3CLpro), and RNA-dependent RNA polymerase (RdRp).AIM. This study aimed to analyse the prevalence, spectrum, and causes of SARS-CoV-2 mutations conferring resistance to approved and pipeline RdRp and 3CLpro inhibitors on the basis of clinical, virological, and genotypic data.DISCUSSION. The authors have analysed the prevalence of SARS-CoV-2 mutations conferring resistance to antivirals (RdRp inhibitors, including remdesivir and molnupiravir, and 3CLpro inhibitors, including paxlovid) in 2021–2024. The results suggest that certain mutations existed prior to the use of these antivirals. The prevalence of resistance-conferring mutations does not exceed 0.5% of the global population. However, the results of clinical and experimental studies demonstrate the possibility of a more than 200-fold reduction in susceptibility to medicinal products and, in particular, the emergence of multidrug-resistant variants. This is especially important for immunocompromised patients. SARS-CoV-2 can persist in such patients for many months, during which spontaneous or selection-driven mutations can render antiviral therapy ineffective. This would create a risk of spreading drug-resistant variants and/or a risk of adverse outcomes for patients.CONCLUSIONS. As COVID-19 treatment coverage increases, there may be a rise in drug-resistant variants of the virus. The presented data indicate the need for genomic epidemiological surveillance, including an analysis of potential targets for medicinal products based on clinical observations. In the future, surveillance data may determine the treatment strategy and the need to develop new antivirals (RdRp and protease inhibitors) adjusted to resistant SARS-CoV-2 variants.